Radnor Capital Management LLC Has $998,000 Stock Position in Eli Lilly and Company (NYSE:LLY)
Radnor Capital Management LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 5,910 shares of the company’s stock after buying an additional 150 shares during the quarter. Radnor Capital Management LLC’s holdings in Eli Lilly and were worth $998,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in LLY. Nuveen Asset Management LLC raised its position in shares of Eli Lilly and by 42.0% in the 2nd quarter. Nuveen Asset Management LLC now owns 8,026,867 shares of the company’s stock valued at $1,317,851,000 after purchasing an additional 2,372,251 shares in the last quarter. FMR LLC raised its position in shares of Eli Lilly and by 7.0% during the 2nd quarter. FMR LLC now owns 29,992,097 shares of the company’s stock valued at $4,924,101,000 after acquiring an additional 1,954,811 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Eli Lilly and in the 3rd quarter valued at about $194,874,000. Two Sigma Advisers LP increased its position in shares of Eli Lilly and by 72.3% in the 2nd quarter. Two Sigma Advisers LP now owns 2,390,116 shares of the company’s stock valued at $392,409,000 after buying an additional 1,003,200 shares in the last quarter. Finally, First Trust Advisors LP increased its holdings in shares of Eli Lilly and by 41.4% in the third quarter. First Trust Advisors LP now owns 1,565,700 shares of the company’s stock worth $231,755,000 after acquiring an additional 458,790 shares in the last quarter. Hedge funds and other institutional investors own 69.85% of the company’s stock.
Several equities research analysts recently commented on the stock. ValuEngine cut shares of Eli Lilly and from a “hold” rating to a “sell” rating in a research report on Saturday, October 17th. JPMorgan Chase & Co. increased their price objective on Eli Lilly and from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, October 16th. Berenberg Bank assumed coverage on Eli Lilly and in a report on Tuesday, September 29th. They set a “hold” rating and a $144.00 target price on the stock. BidaskClub raised Eli Lilly and from a “strong sell” rating to a “sell” rating in a report on Friday, December 11th. Finally, Mizuho increased their price target on shares of Eli Lilly and from $156.00 to $164.00 and gave the company a “neutral” rating in a report on Wednesday, December 16th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $171.13.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Sunday, November 1st. The company reported $1.54 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.71 by ($0.17). Eli Lilly and had a return on equity of 166.45% and a net margin of 24.01%. The company had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.87 billion. During the same quarter in the previous year, the business earned $1.48 EPS. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. Sell-side analysts anticipate that Eli Lilly and Company will post 7.21 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 10th. Shareholders of record on Friday, February 12th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 1.82%. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.74. The ex-dividend date is Thursday, February 11th. Eli Lilly and’s dividend payout ratio (DPR) is presently 49.01%.
In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of Eli Lilly and stock in a transaction on Monday, January 11th. The shares were sold at an average price of $185.49, for a total value of $40,807,800.00. Following the transaction, the insider now owns 111,003,815 shares in the company, valued at approximately $20,590,097,644.35. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.09% of the stock is owned by company insiders.
About Eli Lilly and
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia.
See Also: Forex
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.